{"disease":{"id":"mast-cell-activation-disorder-idiopathic","name":"mast cell activation disorder idiopathic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05652907","title":"Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Quantum Biopharma","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}